Non-Hodgkin’s Lymphoma

March 7, 2019

$12.5M Grant to Help City of Hope Develop New Lymphoma Immunotherapies

News

The National Cancer Institute (NCI) has awarded a five-year $12.5 million grant to City of Hope that may help improve treatment by using a vaccine, develop an immunotherapy to shut ... Read more

January 3, 2019

Phase 3 Trial Testing Biosimilar to Rituxan, JHL1101, in DLBCL Patients Begins

News

Patient dosing has begun in a Phase 3 trial comparing JHL Biotech‘s proposed biosimilar of rituximab JHL1101 to the original medicine, Rituxan (rituximab), in diffuse large B-cell lymphoma (DLBCL), the company announced. The ... Read more

January 2, 2019

Immune Checkpoint Inhibitors Make Lymphoma Respond Better to Future Treatment, Studies Suggest

News

Patients with both Hodgkin’s and non-Hodgkin’s lymphoma who receive immune checkpoint inhibitors as their second-line or later treatment might respond better to their subsequent therapy, even if they failed to ... Read more

December 18, 2018

Depleting White Blood Cells Improves Response to CAR T-cell Therapy in Heavily Treated Patients, Trial Shows

News

A preconditioning chemotherapy regimen given before CD30.CAR-T therapy — a CAR T-cell therapy directed at CD30-positive cancers — seems to improve heavily treated lymphoma patients’ responses to the treatment, a Phase 1/2 ... Read more

December 4, 2018

Truxima Becomes First Biosimilar to Rituxan Approved in US for Non-Hodgkin’s Lymphoma

News

The U.S. Food and Drug Administration has approved Truxima (rituximab-abbs), a biosimilar to Rituxan (rituximab), for three CD20-positive non-Hodgkin’s lymphoma indications, Celltrion and Teva announced. The decision comes less than two months after the FDA’s Oncologic Drugs ... Read more

October 15, 2018

FDA Committee Recommends Truxima’s Approval for 3 Non-Hodgkin’s Lymphoma Indications

News

Truxima (CT-P10) a biosimilar to Rituxan (rituximab), has been unanimously recommended for approval by the U.S. Food and Drug Administration’s Oncologic Drugs Advisory Committee for the treatment of three non-Hodgkin’s lymphoma (NHL) indications, ... Read more

October 12, 2018

Axicabtagene Ciloleucel Gets Japan’s Orphan Drug Designation to Treat Some Non-Hodgkin’s Lymphomas

News

The Japan Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug status to axicabtagene ciloleucel for the treatment of certain aggressive forms of non-Hodgkin’s lymphoma (NHL) namely diffuse large ... Read more

October 11, 2018

Beigene’s Lymphoma Treatment Zanubrutinib Shows High Response Rates in Chinese Phase 1 Trial

News

BeiGene‘s investigational zanubrutinib is showing promising response rates, ranging from 42% to 100%, in several B-cell lymphoma subtypes, preliminary data from a Chinese Phase 1 trial show. Treatment was also well-tolerated. Jun ... Read more

October 8, 2018

Portola’s Cerdulatinib Wins Orphan Drug Designation for Peripheral T-cell Lymphoma

News

The U.S. Food and Drug Administration (FDA) has granted orphan drug status to Portola Pharmaceuticals‘ investigative therapy cerdulatinib to treat patients with peripheral T-cell lymphoma (PTCL), the company announced. Orphan drug designation aims to encourage therapies for ... Read more

September 14, 2018

Zevalin Becomes Available in Canada for Relapsed or Refractory Non-Hodgkin’s Lymphomas

News

Patients in Canada with relapsed or refractory low-grade or follicular B-cell non-Hodgkin’s lymphoma, who produce the CD20 factor, can now be treated with Zevalin (ibritumomab tiuxetan). Servier Canada, Zevalin’s manufacturer, ... Read more